Study finds among outpatients with mild to moderate COVID-19

Study finds among outpatients with mild to moderate COVID-19, treatment with fluvoxamine does not reduce duration of symptoms

Researchers investigate the effects of high-dose fluvoxamine among patients with mild-to-moderate COVID-19.

Related Keywords

United States , American , Scout Chaplin Loebell , Journal Of American Medical Association , American Medical Association , Higher Dose Fluvoxamine , Sustained Recovery , Outpatients With , Image Credit , Coronavirus Disease Covid 19 , Clinical Trial , Coronavirus , Drugs , Placebo , Erotonin ,